ArticleRare tumors2025
Challenges in diagnosing common tumors at uncommon sites.
Article in Rare tumors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rare tumors are a heterogeneous group of neoplasms with low incidence and are usually difficult to diagnose. Certain tumors that are common at specific anatomical locations rarely occur at unexpected locations and cause diagnostic challenges. Although histopathology is central to the diagnosis of these lesions, as with any tumor, ancillary techniques such as immunohistochemistry and molecular studies are often essential. In addition, a multidisciplinary approach that includes clinical, radiological, and biochemical inputs plays an important role in achieving an accurate diagnosis. A total number of 10 benign and malignant neoplastic lesions at rare locations were analyzed. Immunohistochemistry was performed for the required cases. The 10 cases included were: primary nasal meningioma, malignant melanoma of the lacrimal sac, metastatic synovial sarcoma of the thyroid, malignant teratoma of the thyroid, papillary serous cystadenocarcinoma of the paratestis, leiomyoma of the testis, squamous cell carcinoma arising in an epidermoid cyst, intraarticular synovial sarcoma of the knee, Ewing sarcoma of the kidney, and primary plasmacytoma of the breast. Knowledge and awareness of these entities improve the quality of reporting in any individual case. As a group, these lesions require further studies to enhance the understanding of their pathogenesis and patient care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.